Snapshot from Aug 02, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Glucotrack-Lokahi Therapeutics...
Business business combination

Glucotrack-Lokahi Therapeutics Business Combination

Analysis based on 11 articles · First reported Jul 14, 2026 · Last updated Jul 14, 2026

Sentiment
10
Attention
2
Articles
11
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The combination creates a capital-efficient public platform for Lokahi Therapeutics, potentially increasing access to capital and enabling asset acquisition. Glucotrack's legacy CBGM business continues as a subsidiary, providing focused execution while the combined entity pursues broader opportunities.

biotechnology medical devices
Event Summary

Glucotrack, Inc. (Nasdaq: GCTK) completed its strategic business combination with Lokahi Therapeutics on July 14, 2026. The transaction establishes a publicly listed platform for identifying, acquiring, and advancing healthcare assets. Lokahi Therapeutics becomes the operating and controlling business, with its securityholders receiving Glucotrack common and convertible preferred stock, expected to result in approximately 90% ownership on a fully diluted basis. The combined company will continue Glucotrack's continuous blood glucose monitoring (CBGM) technology as a separate subsidiary. Erik Emerson was appointed CEO of the combined company, and Paul Goodson as CTO and CEO of the CBGM subsidiary.

Key Actions
100 Glucotrack completed business combination Bicara Therapeutics
60 Glucotrack appointed CEO Erik Emerson
50 Glucotrack appointed CTO Paul Goodson
Entities Involved
stock
Glucotrack
Glucotrack completed a business combination with Lokahi Therapeutics, becoming a publicly listed platform. Its legacy CBGM business will operate as a separate subsidiary.
Importance 100.0 Sentiment 10.0
per
Erik Emerson
Erik Emerson was appointed CEO of the combined company, providing unified leadership.
Importance 50.0 Sentiment 0.0
per
Paul Goodson
Paul Goodson was appointed CTO of the combined company and CEO of the CBGM subsidiary.
Importance 40.0 Sentiment 0.0
priv
Bicara Therapeutics
Importance 30.0 Sentiment 0.0
exch
Nasdaq
The combined company will continue to be listed on Nasdaq, subject to listing requirements.
Importance 20.0 Sentiment 0.0
govactor
United States — United States Securities and Exchange Commission
The transaction involves filings with the SEC, including forward-looking statements and risk factors.
Importance 10.0 Sentiment 0.0
govactor
United States — Food and Drug Administration
The CBGM technology is an investigational device subject to FDA approval.
Importance 10.0 Sentiment 0.0
Relationships
Nasdaq regulated ↔ United States — United States Securities and Exchange Commission Nasdaq operates as a registered national securities exchange under the direct oversight and regulatory authority of the
United States — United States Securities and Exchange Commission related ↔ United States — Food and Drug Administration
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.